PARP1 and gastric cancer: Thus, identifying new prognostic factors other than, for example, pathological stage to accurately identify patients at higher risk of recurrence may improve our accuracy in determining recurrence risk [23], similar to PARP9.A comprehensive exploration of the oncogenic mechanisms associated with PARP in GC may provide valuable insights for molecular interventions in GC therapy.